Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

NormOxys raises $17.5M in Series B financing round

NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.

24 May 2010

Phase 1 clinical trial of OXY111A initiated

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.

24 May 2010

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

David H. Fater, CEO of Vicor Technologies, Inc., today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca Trial using its PD2i- algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i- nonlinear algorithm and software.

20 May 2010

ABBOTT PRISM Chagas test receives FDA approval

Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug."

19 May 2010

Abiomed's Impella revenue for full fiscal year 2010 up 59% to $57.8 million

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2010 revenue of $23.0 million, up 17% compared to revenue of $19.6 million for the same period of fiscal 2009.

19 May 2010

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Geron Corporation today announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF). The data show that administration of TAT153 increased telomerase activity in the lung tissue, reduced inflammation, preserved functional lung tissue, slowed disease progression and attenuated loss of pulmonary function.

19 May 2010

eMedonline telemonitoring system developed to help patients transition from inpatient to outpatient setting

A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.

19 May 2010

Market for telehealth and home health monitoring to grow up to $7.7 billion by 2012: Survey

AMERICAN TELEMEDICINE ASSOCIATION ANNUAL MEETING - Health care delivery in the United States will undergo dramatic changes over the next 10 years through the adoption of telehealth, according to a national survey of health care and information technology professionals sponsored by Intel Corporation.

19 May 2010

REVEAL risk score calculator provides innovative approach to better understand PAH

Actelion Ltd announced today that findings from the REVEAL Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension according to data presented at the American Thoracic Society's Annual International Conference.

18 May 2010

Electrical muscle stimulation prevents critical illness polynueromyopathy

Electrical muscle stimulation (EMS) can prevent critical illness polyneuromyopathy (CIPNM), according to Greek researchers. CIPNM is an acquired limb and respiratory muscle weakness that is a common and serious problem among intensive care unit patients, and can result in prolonged ICU and hospital stay. EMS can also shorten the duration of weaning from mechanical ventilation and the length of ICU stay.

18 May 2010

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Response Biomedical Corporation today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada.

18 May 2010

Apnex HGNS System shows promising results in people suffering from OSA

Apnex Medical announced today that preliminary data from a first-in-man clinical study showed significant improvements in sleep for people suffering from obstructive sleep apnea. The Apnex HGNS™ System, developed by the St. Paul-based company, is a device designed to treat OSA, which is a serious life-threatening illness characterized by fragmented sleep and excessive day-time sleepiness.

18 May 2010

Cardiocom releases new pulse oximeter

Cardiocom today announced the release of its new pulse oximeter. Cardiocom's internally developed pulse oximeter offers better integration with its telehealth platform. Cardiocom designs and manufactures telehealth communication devices and vital sign peripherals including: blood pressure system, weight scale, and now offers its new pulse oximeter.

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

New data from MVP trial on ICDs shows health care use burden

Medtronic, Inc. today released new data from the MVP trial that implantable defibrillator patients receiving anti-tachycardia pacing were less likely to have health care utilization after treatment as compared to those receiving shock therapy.

17 May 2010

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Long-term, regular use of vitamin E in women 45 years of age and older may help decrease the risk of chronic obstructive pulmonary disease by about 10 percent in both smokers and non-smokers, according to a study conducted by researchers at Cornell University and Brigham and Women's Hospital.

17 May 2010

Heart Failure News and Research

Further Reading

NormOxys raises $17.5M in Series B financing round

Phase 1 clinical trial of OXY111A initiated

European researchers define research priorities in biogerontology

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Genentech to present new data for targeted cancer medicines at 46th ASCO

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

ABBOTT PRISM Chagas test receives FDA approval

Abiomed's Impella revenue for full fiscal year 2010 up 59% to $57.8 million

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

eMedonline telemonitoring system developed to help patients transition from inpatient to outpatient setting

Market for telehealth and home health monitoring to grow up to $7.7 billion by 2012: Survey

REVEAL risk score calculator provides innovative approach to better understand PAH

Electrical muscle stimulation prevents critical illness polynueromyopathy

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Apnex HGNS System shows promising results in people suffering from OSA

Cardiocom releases new pulse oximeter

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

New data from MVP trial on ICDs shows health care use burden

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News